Peringatan Keamanan

Oral LD50 values of doxepin in mouse and rat are 180 mg/kg and 147 mg/kg, respectively.MSDS In an overdose state, symptoms of convulsions, dysrhythmias, coma, severe hypotension, central nervous system depression, changes on electrocardiography results and death have been observed.T249

On fertility studies, doxepin was shown to increase the copulatory interval, decrease the corpora lutea, decrease implantation, decreased the number of viable embryos, decrease litter size, increase the number of abnormal sperm and decrease the sperm motility. There is no evidence indicating carcinogenic and mutagenic potential.FDA label

Doxepin

DB01142

small molecule approved investigational

Deskripsi

Doxepin is a psychotropic agent with antidepressant and anxiolytic properties.T559 It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to cidoxepin. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture.T83

In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including amitriptyline, clomipramine, desipramine, imipramine, nortriptyline, protriptyline and trimipramine.L5977

Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.L5971 However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.L5974

Struktur Molekul 2D

Berat 279.3761
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean elimination half-life is reported to be of 15 hours.[T388]
Volume Distribusi The mean apparent volume of distribution of doxepin is reported to be of 20 L/kg.[T388]
Klirens (Clearance) The mean total apparent plasma clearance of a single oral dose of 50 mg doxepin in healthy individuals is 0.93 l/hr/kg.[A1945]

Absorpsi

Doxepin is moderately absorbed following oral ingestion with a bioavailability of 30%.T388 The median peak concentration of doxepin ranges from 8.8-45.8 ng/ml and it is achieved 3.5 hours after initial administration. Its absorption is increased with concomitant administration of a high-fat meal.L5995

Metabolisme

Doxepin is extensively metabolized to N-desmethyldoxepin which is a biologically active metabolite and other inactive metabolites.A177172 The first-pass metabolism accounts for 55-87% of the administered dose.A177196 After, the secondary metabolism is driven by the transformation of N-desmethyldoxepin to its glucuronide conjugates.L5995 The main metabolic enzymes involved in the transformation of doxepin are the members of the cytochrome P450 family, CYP2C19 and CYP2D6 with minor involvement of CYP1A2 and CYP2C9.L5995

Rute Eliminasi

The elimination profile of doxepin is presented as biphasic.A1945 It is excreted in the urine mainly in the form of glucuronide conjugates. Less than 3% of a doxepin dose is excreted in the urine as parent compound or nordoxepin.L1347

Farmakogenomik

8 Varian
CYP2D6 (rs35742686)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.

CYP2D6 (rs3892097)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.

CYP2D6 (None)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.

CYP2D6 (rs5030655)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.

CYP2C19 (rs4244285)

The presence of this polymorphism in CYP2C19 is associated with poor metabolism of doxepin.

CYP2C19 (rs4986893)

The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of doxepin.

CYP2D6 (rs1135824)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.

CYP2D6 (rs28371733)

The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol. Co-administration may enhance CNS adverse effects such as drowsiness and sedation.
  • 2. Avoid St. John's Wort. Co-administration may lead to decreased serum concentrations of doxepin.

Interaksi Obat

2361 Data
Deferasirox The serum concentration of Doxepin can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Doxepin can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Doxepin can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.
Remikiren Doxepin may decrease the antihypertensive activities of Remikiren.
Guanadrel Doxepin may decrease the antihypertensive activities of Guanadrel.
Olmesartan Doxepin may decrease the antihypertensive activities of Olmesartan.
Minoxidil Doxepin may decrease the antihypertensive activities of Minoxidil.
Trandolapril Doxepin may decrease the antihypertensive activities of Trandolapril.
Benazepril Doxepin may decrease the antihypertensive activities of Benazepril.
Candoxatril Doxepin may decrease the antihypertensive activities of Candoxatril.
Nitroglycerin Doxepin may decrease the antihypertensive activities of Nitroglycerin.
Cryptenamine Doxepin may decrease the antihypertensive activities of Cryptenamine.
Eprosartan Doxepin may decrease the antihypertensive activities of Eprosartan.
Quinapril Doxepin may decrease the antihypertensive activities of Quinapril.
Deserpidine Doxepin may decrease the antihypertensive activities of Deserpidine.
Saprisartan Doxepin may decrease the antihypertensive activities of Saprisartan.
Spirapril Doxepin may decrease the antihypertensive activities of Spirapril.
Diethylnorspermine Doxepin may decrease the antihypertensive activities of Diethylnorspermine.
Temocapril Doxepin may decrease the antihypertensive activities of Temocapril.
Rauwolfia serpentina root Doxepin may decrease the antihypertensive activities of Rauwolfia serpentina root.
Angiotensin 1-7 Doxepin may decrease the antihypertensive activities of Angiotensin 1-7.
Imidapril Doxepin may decrease the antihypertensive activities of Imidapril.
BQ-123 Doxepin may decrease the antihypertensive activities of BQ-123.
Zofenopril Doxepin may decrease the antihypertensive activities of Zofenopril.
Guanoxan Doxepin may decrease the antihypertensive activities of Guanoxan.
Delapril Doxepin may decrease the antihypertensive activities of Delapril.
Vincamine Doxepin may decrease the antihypertensive activities of Vincamine.
Linsidomine Doxepin may decrease the antihypertensive activities of Linsidomine.
Guanoxabenz Doxepin may decrease the antihypertensive activities of Guanoxabenz.
Tolonidine Doxepin may decrease the antihypertensive activities of Tolonidine.
Endralazine Doxepin may decrease the antihypertensive activities of Endralazine.
Cadralazine Doxepin may decrease the antihypertensive activities of Cadralazine.
Bietaserpine Doxepin may decrease the antihypertensive activities of Bietaserpine.
Guanazodine Doxepin may decrease the antihypertensive activities of Guanazodine.
Methoserpidine Doxepin may decrease the antihypertensive activities of Methoserpidine.
Guanoclor Doxepin may decrease the antihypertensive activities of Guanoclor.
Tocopherylquinone Doxepin may decrease the antihypertensive activities of Tocopherylquinone.
Benazeprilat Doxepin may decrease the antihypertensive activities of Benazeprilat.
Fosinoprilat Doxepin may decrease the antihypertensive activities of Fosinoprilat.
Ramiprilat Doxepin may decrease the antihypertensive activities of Ramiprilat.
Perindoprilat Doxepin may decrease the antihypertensive activities of Perindoprilat.
Quinaprilat Doxepin may decrease the antihypertensive activities of Quinaprilat.
Pinacidil Doxepin may decrease the antihypertensive activities of Pinacidil.
Riociguat Doxepin may decrease the antihypertensive activities of Riociguat.
Aliskiren Doxepin may decrease the antihypertensive activities of Aliskiren.
Enalapril Doxepin may decrease the antihypertensive activities of Enalapril.
Captopril Doxepin may decrease the antihypertensive activities of Captopril.
Cilazapril Doxepin may decrease the antihypertensive activities of Cilazapril.
Ambrisentan Doxepin may decrease the antihypertensive activities of Ambrisentan.
Selexipag Doxepin may decrease the antihypertensive activities of Selexipag.
Ramipril Doxepin may decrease the antihypertensive activities of Ramipril.
Perindopril Doxepin may decrease the antihypertensive activities of Perindopril.
Levamlodipine Doxepin may decrease the antihypertensive activities of Levamlodipine.
Azilsartan medoxomil Doxepin may decrease the antihypertensive activities of Azilsartan medoxomil.
Diazoxide Doxepin may decrease the antihypertensive activities of Diazoxide.
Buprenorphine Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Hydrocodone Doxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Doxepin can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Doxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Doxepin may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Orphenadrine Doxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Doxepin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Pramipexole Doxepin may increase the sedative activities of Pramipexole.
Ropinirole Doxepin may increase the sedative activities of Ropinirole.
Rotigotine Doxepin may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Doxepin.
Suvorexant Doxepin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Thalidomide Doxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Doxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Dabrafenib The serum concentration of Doxepin can be decreased when it is combined with Dabrafenib.
Aclidinium The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Doxepin.
Mirabegron The risk or severity of urinary retention can be increased when Doxepin is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Doxepin is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Doxepin.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Doxepin.
Tiotropium The risk or severity of adverse effects can be increased when Doxepin is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Doxepin is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Doxepin is combined with Umeclidinium.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with Doxepin.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with Doxepin.
Omapatrilat Doxepin may decrease the antihypertensive activities of Omapatrilat.
Rescinnamine Doxepin may decrease the antihypertensive activities of Rescinnamine.
Epicaptopril The risk or severity of hypertension can be increased when Doxepin is combined with Epicaptopril.
1-benzylimidazole The risk or severity of hypertension can be increased when Doxepin is combined with 1-benzylimidazole.
Saralasin The risk or severity of hypertension can be increased when Doxepin is combined with Saralasin.
Tyramine The risk or severity of hypertension can be increased when Doxepin is combined with Tyramine.
Atipamezole The risk or severity of hypertension can be increased when Doxepin is combined with Atipamezole.
Idazoxan The risk or severity of hypertension can be increased when Doxepin is combined with Idazoxan.
Tramazoline The risk or severity of hypertension can be increased when Doxepin is combined with Tramazoline.
Fenozolone The risk or severity of hypertension can be increased when Doxepin is combined with Fenozolone.
Xenon The risk or severity of hypertension can be increased when Doxepin is combined with Xenon.

Target Protein

Histamine H1 receptor HRH1
Histamine H2 receptor HRH2
Sodium-dependent noradrenaline transporter SLC6A2
Sodium-dependent serotonin transporter SLC6A4
5-hydroxytryptamine receptor 2A HTR2A
5-hydroxytryptamine receptor 2B HTR2B
5-hydroxytryptamine receptor 2C HTR2C
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M4 CHRM4
Muscarinic acetylcholine receptor M5 CHRM5
Alpha-1A adrenergic receptor ADRA1A
Alpha-1B adrenergic receptor ADRA1B
Alpha-1D adrenergic receptor ADRA1D
5-hydroxytryptamine receptor 1A HTR1A
5-hydroxytryptamine receptor 6 HTR6
Histamine H4 receptor HRH4
Voltage-gated inwardly rectifying potassium channel KCNH2 KCNH2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25364337
    Rojas-Fernandez CH, Chen Y: Use of ultra-low-dose (
  • PMID: 30000240
    Authors unspecified: Doxepin .
  • PMID: 7293791
    Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6.
  • PMID: 17685877
    Singh H, Becker PM: Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
  • PMID: 9788530
    Negrusz A, Moore CM, Perry JL: Detection of doxepin and its major metabolite desmethyldoxepin in hair following drug therapy. J Anal Toxicol. 1998 Oct;22(6):531-6.
Textbook
  • Pagliaro L. and Pagliaro A. (1999). Psychologists' psychotropic drug reference. Taylor and Francis.
  • ISBN: 9780521683500
    Stephen M. Stahl (2006). Essential Psychopharmacology: The Prescriber's Guide: Revised and Updated Edition. Cambridge University Press.
  • Elks J. and Ganellin C.R. (1990). The dictionary of drugs. Springer Science.
  • ISBN: 978-146-7263-085
    Bishop M. (2015). Clinical chemistry: techniques, principles and correlations (6th ed.). Content Technologies Inc.

Contoh Produk & Brand

Produk: 411 • International brands: 4
Produk
  • Alti-doxepin - Cap 10mg
    Capsule • 10 mg / cap • Oral • Canada • Generic • Approved
  • Alti-doxepin-cap 25mg
    Capsule • 25 mg / cap • Oral • Canada • Generic • Approved
  • Alti-doxepin-cap 50mg
    Capsule • 50 mg / cap • Oral • Canada • Generic • Approved
  • Alti-doxepin-cap 75mg
    Capsule • 75 mg / cap • Oral • Canada • Generic • Approved
  • Doxepin
    Tablet, film coated • 3 mg/1 • Oral • US • Generic • Approved
  • Doxepin
    Tablet, film coated • 6 mg/1 • Oral • US • Generic • Approved
  • Doxepin
    Capsule • 100 mg • Oral • Canada • Approved
  • Doxepin
    Capsule • 150 mg • Oral • Canada • Approved
Menampilkan 8 dari 411 produk.
International Brands
  • Adapin — PennwaIt
  • Aponal — Pfizer
  • Doxepine — Shou Chan
  • Quitaxon — Lexphar

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul